Brought to you by 
Roche buys remaining 33% stake in Genentech
17 Feb 2000
Executive Summary
In a $3.68bn deal, Roche exercised an option it gained in 1990 (and extended in 1995) to buy the remaining 33% of Genentech's outstanding common shares; the option would have expired at the end of June. It previously owned 65% of the company.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche buys remaining 33% stake in Genentech
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice